CN104474478A - Traditional Chinese medicine for treating non-alcoholic fatty liver disease due to qi-stagnation and blood stasis - Google Patents
Traditional Chinese medicine for treating non-alcoholic fatty liver disease due to qi-stagnation and blood stasis Download PDFInfo
- Publication number
- CN104474478A CN104474478A CN201410785105.2A CN201410785105A CN104474478A CN 104474478 A CN104474478 A CN 104474478A CN 201410785105 A CN201410785105 A CN 201410785105A CN 104474478 A CN104474478 A CN 104474478A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- stagnation
- fatty liver
- blood stasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine for treating non-alcoholic fatty liver disease due to qi-stagnation and blood stasis. The traditional Chinese medicine is prepared from firethorn root, corydalis amabilis, trevesia palmata, leonurus flower, ligusticum wallichii, fiveleaf akebia fruit, curcuma aromatica, siberian walking fern, szechwan Chinaberry fruit and trogopterus dung. The traditional Chinese medicine is clinically used for treating non-alcoholic fatty liver disease due to qi-stagnation and blood stasis.
Description
Technical field
The invention belongs to technical field of Chinese medicines, especially relate to a kind of Chinese medicine for the treatment of qi stagnation and blood stasis type non-alcoholic fatty liver disease.
Background technology
Non-alcoholic fatty liver disease (NAFLD) be to become without excessive drinking history (Ethanol intake amount <20g/d) and hepatic cell fattydegeneration, balloon sample, dispersivity lobule mild inflammation and (or) central veins of liver, collagen deposition etc. is clinicopathological characteristics around sinus hepaticus chronic hepatic diseases, except finger caused by ethanol and other clear and definite damage liver factors; pathological changes main body, at lobules of liver, stores up the clinical pathology syndrome for pathological characters with diffusivity hepatocyte Macrovesicular steatosis and fat.The modal Symptoms of qi stagnation and blood stasis type non-alcoholic fatty liver disease is the twinge of the breast side of body, and side of body rib feeling of distension and oppression, pain is walked to alter or tenderness, woman's dysmenorrhea or amenorrhea, and dark menses accompanies clot, and purplish tongue is dark or have ecchymosis, stringy pulse or puckery.There is no the specially good effect means for the treatment of qi stagnation and blood stasis type non-alcoholic fatty liver disease at present, the therapeutic effect of some chemicalses and safety issue are still needed and are checked further.The treatment by Chinese herbs qi stagnation and blood stasis type non-alcoholic fatty liver disease that the present invention prepares, achieves good effect.
Summary of the invention
The object of the present invention is to provide that a kind of therapeutic effect is good, effective percentage is high, Chinese medicine to the treatment qi stagnation and blood stasis type non-alcoholic fatty liver disease of human non-toxic's side effect.
The object of the present invention is achieved like this, according to Chinese medical theory, utilizes the property of medicine of Chinese medicine uniqueness, adopts Radix Pyracanthae Fortuneanae, Rhizoma Corydalis Decumbentis, Medulla Trevesiae palmatae, Flos leonuri, Rhizoma Chuanxiong, Fructus Akebiae, Radix Curcumae, Herba Camptosori Sibirici, Fructus Toosendan, Oletum Trogopterori, according to certain compatibility requirement, through being processed into.
Prepare Chinese medicine of the present invention to be made up of following raw material medicaments: Radix Pyracanthae Fortuneanae 40-60 part, Rhizoma Corydalis Decumbentis 20-30 part, Medulla Trevesiae palmatae 20-30 part, Flos leonuri 15-25 part, Rhizoma Chuanxiong 15-25 part, Fructus Akebiae 15-25 part, Radix Curcumae 15-25 part, Herba Camptosori Sibirici 10-15 part, Fructus Toosendan 8-10 part, Oletum Trogopterori 5-10 part.
Optimum weight part of raw material of Chinese medicine medicine of the present invention is: Radix Pyracanthae Fortuneanae 50 parts, Rhizoma Corydalis Decumbentis 25 parts, Medulla Trevesiae palmatae 25 parts, Flos leonuri 20 parts, Rhizoma Chuanxiong 20 parts, Fructus Akebiae 20 parts, Radix Curcumae 20 parts, Herba Camptosori Sibirici 12 parts, Fructus Toosendan 9 parts, Oletum Trogopterori 7 parts.
The pharmacological action of Chinese medicine of the present invention is as follows:
Radix Pyracanthae Fortuneanae: sour, puckery, flat.Return liver, kidney channel.Clearing away heat and cooling blood, blood-activating analgetic.Clinical in hectic fever night sweat, discharging fresh blood stool, metrorrhagia, conjunctival congestion and swelling pain, acute toothache, traumatic injury, the diseases such as impairment caused by overstrain pain in the lumbar region.
Rhizoma Corydalis Decumbentis: bitter, pungent, cool.Return liver, kidney channel.Expelling wind and removing dampness, relaxing muscles and tendons to promote blood circulation, removing obstruction in the collateral to relieve pain, blood pressure lowering.For rheumatic arthritis, apoplectic hemiplegia, sciatica, poliomyelitis sequela, lumbar muscle strain, hypertension etc.
Medulla Trevesiae palmatae: micro-hardship, flat.Blood-activating analgetic.Clinical in traumatic injury, wound, lumbago.
Flos leonuri: sweet, bitter, cold.Nourish blood, invigorate blood circulation, diuretic.For anemia, carbuncle pyogenic infections from tumour or sore, amenorrhea due to stagnation of blood, dysmenorrhea, the diseases such as prolonged lochia.
Rhizoma Chuanxiong: pungent, warm, returns liver, gallbladder, heart channel.Blood-activating and qi-promoting, wind-expelling pain-stopping.For stagnation of QI and blood, rheumatic arthralgia.
Fructus Akebiae: micro-hardship, property are flat.Return liver, stomach, urinary bladder channel.Dispersing the stagnated liver-QI for regulating the stomach, promoting blood circulation and stopping pain, hard masses softening and resolving, diuresis.For stagnation of liver-QI and stomach-QI, gastral cavity abdomen, the side of body help distending pain, and diet does not disappear, and dysentery is just let out, hernia pain, lumbago, amenorrhea dysmenorrhea, goiter scrofula, malignant tumor etc.
Radix Curcumae: bitter, acrid, cold, returns liver, gallbladder, heart channel.Blood-activating and qi-promoting pain relieving, resolving depression clears away heart-fire, promoting the function of the gallbladder to alleviate jaundice, removing heat from blood.For the card of calentura coma, epilepsy unconsciousness due to blockage of phlegm.
Herba Camptosori Sibirici: light, flat.GUIXIN warp.Blood circulation promoting and blood stasis dispelling, hemostasis, removing toxic substances.For thromboangiitis obliterans, hemiplegia, metrorrhagia, traumatic hemorrhage, neurodermatitis, ulcer of the lower limb.
Fructus Toosendan: bitter, cold, returns liver, stomach, small intestinal, urinary bladder channel.Promoting the circulation of QI to relieve pain, parasite killing treats tinea.For pain cards all caused by pathogenic fire derived from stagnation of liver-QI.
Oletum Trogopterori: bitter, salty, sweet, temperature.Return Liver Channel.Promoting blood circulation and stopping pain, removing stasis to stop bleeding.For all cards of stagnation of blood stasis.
Non-alcoholic fatty liver disease belongs to multiple and frequently-occurring disease, and dietary structure changes, and the food intake of higher fatty acid property is too much main Primary factors.The harm of primary disease, more and more causes the attention of doctor and numerous patients.Control protopathy because of, improve dietary structure, increase sports, health invigorating becomes the task of top priority.For the patient fallen ill, use Chinese medicine Comprehensive Treatment, curative effect is affirmative.Coryza Treated by Syndrome Differentiation primary disease, according to the negative and positive cold and heat and asthenia and sthenia situation of human body, plus-minus uses, and how can cure or relief of symptoms.Radix Pyracanthae Fortuneanae clearing away heat and cooling blood of the present invention, blood-activating analgetic, for monarch drug, Rhizoma Corydalis Decumbentis relaxing muscles and tendons to promote blood circulation, removing obstruction in the collateral to relieve pain, Medulla Trevesiae palmatae blood-activating analgetic, for ministerial drug, Flos leonuri nourishes blood, invigorate blood circulation, diuretic, Rhizoma Chuanxiong blood-activating and qi-promoting, wind-expelling pain-stopping, Fructus Akebiae dispersing the stagnated liver-QI for regulating the stomach, promoting blood circulation and stopping pain, the pain relieving of Radix Curcumae blood-activating and qi-promoting, resolving depression clears away heart-fire, Herba Camptosori Sibirici blood circulation promoting and blood stasis dispelling, hemostasis, removing toxic substances, Fructus Toosendan promoting the circulation of QI to relieve pain, Oletum Trogopterori promoting blood circulation and stopping pain, blood stasis dispelling, compatibility uses, play blood-activating analgetic altogether, the merit of promoting flow of QI and blood, reach the object for the treatment of qi stagnation and blood stasis type non-alcoholic fatty liver disease.
Chinese medicine of the present invention is used in 2008 to 2012 the routine patients of clinical observation qi stagnation and blood stasis type non-alcoholic fatty liver disease disease 45, and clinical report is as follows:
1, physical data
In 45 routine patients, women 27 example, male 18 example, minimum 37 years old of age, maximum 42 years old, 38.7 years old mean age.
2, diagnostic criteria
With reference to " Chinese medical disease Standardization of diagnosis and curative effect ":
1. without history of drinking history or drink and amount to amount of alcohol, male is < 40g weekly.2. except, viral hepatitis, drug-induced liver disease, full gastrointestinal nutrition, hepatolenticular degeneration etc. can cause the specified disease of fatty liver.3., except primary disease clinical manifestation, weak, nonspecific symptom and the sign such as dyspepsia, dull pain in liver, hepatosplenomegaly can be accompanied.4. can there is the overweight and (or) Abdominal obesity of weight, fasting glucose increases, the metabolism syndrome associated change such as blood fat disorder, hypertension.5. serum transaminase and GGT level can have and gently increase (< 5 times of Upper Limit of Normal Values) to mild or moderate, usually increase to master with ALT.6. liver imageology performance meets diffusivity fatty liver imaging diagnosis main points.7. liver biopsy Histological change meets the pathological diagnosis main points of fatty liver.Above 7 possess 1. ~ 6. or the 7. can determine diagnosis any one of item 5. item and the.
Qi stagnation and blood stasis type non-alcoholic fatty liver disease clinical symptoms: breast side of body twinge, side of body rib feeling of distension and oppression, pain is walked to alter or tenderness, woman's dysmenorrhea or amenorrhea, and dark menses accompanies clot, and purplish tongue is dark or have ecchymosis, stringy pulse or puckery.
3, Therapeutic Method
3.1 prescriptions: Radix Pyracanthae Fortuneanae 50g, Rhizoma Corydalis Decumbentis 25g, Medulla Trevesiae palmatae 25g, Flos leonuri 20g, Rhizoma Chuanxiong 20g, Fructus Akebiae 20g, Radix Curcumae 20g, Herba Camptosori Sibirici 12g, Fructus Toosendan 9g, Oletum Trogopterori 7g.
3.2 preparation methoies: said medicine routinely technique makes decoction.
3.3 instructions of taking: each 1 dose, every day 2 times 30 days was 1 course for the treatment of.
3.4 observation index: the change of record patient symptom, sign and diet, weight situation.Row ultrasound diagnosis liver, gallbladder, pancreas, spleen before and after treatment, venous blood samples detects serum lipids, liver function level, comprises T-CHOL (TC), triacylglycerol (TG), alanine aminotransferase (ALT), aspartate amino transferase (AST).
4, therapeutic outcome:
4.1 with reference to " Chinese medical disease Standardization of diagnosis and curative effect ":
Clinical cure: clinical symptoms and sign disappear, liver B ultrasonic or CT examination, lab testing recover normal;
Effective: clinical symptoms and sign are obviously improved, liver B ultrasonic or CT examination, take a turn for the better obviously, and the indices of lab testing declines more than 40%;
Do not heal: clinical symptoms and sign are improved not obvious, liver B ultrasonic or CT examination treatment front and back are without significant change, and the indices of lab testing is without obvious decline.
4.2 results: in 45 routine patients, clinical cure 21 example (46.7%), effective 18 examples (40%), do not heal 6 examples (13.3%), and total effective rate is 86.7%.
5, model case
5.1 flood certain, man, 42 years old, liver function shows glutamate pyruvate transaminase (ALT) 95U/L, glutamic oxaloacetic transaminase, GOT (AST) 76U/L, glutamyl transpeptidase (r-GGT): 87U/L, blood fat: cholesterol 6.2mmol/l, triglyceride 5.5mmol/L.CT shows: severe fatty liver.Take medicine of the present invention, treat 1 course for the treatment of, all diseases alleviate, and continue to take 3 courses for the treatment of, and check liver function, blood fat are all normal, and CT shows: liver and gall spleen pancreas shows no obvious abnormalities, recovery from illness.Follow up a case by regular visits to after half a year without recurrence.
5.2 tall certain, female, 38 years old, once did the inspections such as liver function, blood fat, color ultrasound, CT, was diagnosed as qi stagnation and blood stasis type non-alcoholic fatty liver disease.Blood fat is higher, and transaminase is high.Examine and see that purplish tongue is dark, stringy pulse.Take medicine of the present invention, every day 1 dose, after 1 course for the treatment of, all diseases alleviate, and continue to take 1 course for the treatment of, and check liver function, blood fat are all normal, and CT shows: liver and gall spleen pancreas shows no obvious abnormalities, recovery from illness.Follow up a case by regular visits to after half a year without recurrence.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is further illustrated, and this embodiment following does not only limit the present invention for illustration of the present invention.
Embodiment 1, a kind of Chinese medicine for the treatment of qi stagnation and blood stasis type non-alcoholic fatty liver disease, it is made up of following raw material medicaments: Radix Pyracanthae Fortuneanae 60g, Rhizoma Corydalis Decumbentis 30g, Medulla Trevesiae palmatae 30g, Flos leonuri 25g, Rhizoma Chuanxiong 25g, Fructus Akebiae 25g, Radix Curcumae 25g, Herba Camptosori Sibirici 15g, Fructus Toosendan 10g, Oletum Trogopterori 10g.
Embodiment 2, a kind of Chinese medicine for the treatment of qi stagnation and blood stasis type non-alcoholic fatty liver disease, it is made up of following raw material medicaments: Radix Pyracanthae Fortuneanae 50g, Rhizoma Corydalis Decumbentis 25g, Medulla Trevesiae palmatae 25g, Flos leonuri 20g, Rhizoma Chuanxiong 20g, Fructus Akebiae 20g, Radix Curcumae 20g, Herba Camptosori Sibirici 12g, Fructus Toosendan 9g, Oletum Trogopterori 7g.
Embodiment 3, a kind of Chinese medicine for the treatment of qi stagnation and blood stasis type non-alcoholic fatty liver disease, it is made up of following raw material medicaments: Radix Pyracanthae Fortuneanae 40g, Rhizoma Corydalis Decumbentis 20g, Medulla Trevesiae palmatae 20g, Flos leonuri 15g, Rhizoma Chuanxiong 15g, Fructus Akebiae 15g, Radix Curcumae 15g, Herba Camptosori Sibirici 10g, Fructus Toosendan 8g, Oletum Trogopterori 5g.
Claims (2)
1. treat a Chinese medicine for qi stagnation and blood stasis type non-alcoholic fatty liver disease, it is characterized in that comprising following crude drug:
Radix Pyracanthae Fortuneanae 40-60 part, Rhizoma Corydalis Decumbentis 20-30 part, Medulla Trevesiae palmatae 20-30 part, Flos leonuri 15-25 part, Rhizoma Chuanxiong 15-25 part, Fructus Akebiae 15-25 part, Radix Curcumae 15-25 part, Herba Camptosori Sibirici 10-15 part, Fructus Toosendan 8-10 part, Oletum Trogopterori 5-10 part.
2. Chinese medicine according to claim 1, is characterized in that comprising following crude drug:
Radix Pyracanthae Fortuneanae 50 parts, Rhizoma Corydalis Decumbentis 25 parts, Medulla Trevesiae palmatae 25 parts, Flos leonuri 20 parts, Rhizoma Chuanxiong 20 parts, Fructus Akebiae 20 parts, Radix Curcumae 20 parts, Herba Camptosori Sibirici 12 parts, Fructus Toosendan 9 parts, Oletum Trogopterori 7 parts.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410785105.2A CN104474478A (en) | 2014-12-18 | 2014-12-18 | Traditional Chinese medicine for treating non-alcoholic fatty liver disease due to qi-stagnation and blood stasis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410785105.2A CN104474478A (en) | 2014-12-18 | 2014-12-18 | Traditional Chinese medicine for treating non-alcoholic fatty liver disease due to qi-stagnation and blood stasis |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104474478A true CN104474478A (en) | 2015-04-01 |
Family
ID=52749179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410785105.2A Pending CN104474478A (en) | 2014-12-18 | 2014-12-18 | Traditional Chinese medicine for treating non-alcoholic fatty liver disease due to qi-stagnation and blood stasis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104474478A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102225179A (en) * | 2011-05-31 | 2011-10-26 | 刘东升 | Traditional Chinese preparation for treating non-alcoholic fatty liver |
CN103432528A (en) * | 2013-08-23 | 2013-12-11 | 冯庄明 | Chinese medicinal preparation for treating non-alcoholic fatty liver disease |
-
2014
- 2014-12-18 CN CN201410785105.2A patent/CN104474478A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102225179A (en) * | 2011-05-31 | 2011-10-26 | 刘东升 | Traditional Chinese preparation for treating non-alcoholic fatty liver |
CN103432528A (en) * | 2013-08-23 | 2013-12-11 | 冯庄明 | Chinese medicinal preparation for treating non-alcoholic fatty liver disease |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102205108B (en) | Traditional Chinese medicine preparation for treating gastric ulcer and preparation method thereof | |
CN103007081B (en) | Traditional Chinese medicine composition for curing non-alcoholic fatty liver disease | |
CN104383336B (en) | A kind of Chinese medicine preparation for renal calculus postoperative care and preparation method | |
CN103638456B (en) | A kind of Chinese medicine for the treatment of liver cirrhosis and preparation method thereof | |
CN105816802A (en) | Orally-taken traditional Chinese medicine preparation for treating wind heat-type common cold | |
CN103100003B (en) | Traditional Chinese medicine composition for treating acute gouty arthritis | |
CN103083573B (en) | Traditional Chinese medicine used for treating alcoholic fatty liver | |
CN104888081A (en) | Instant herbal medicine for treating kidney-yang deficiency type diarrhea associated with menstruation | |
CN104667249B (en) | A kind of Chinese medicine composition for treating primary dysmenorrhea | |
CN103055218A (en) | Traditional Chinese medicine composition for treating neonatal jaundice and preparation method thereof | |
CN103550528B (en) | Chinese herbal preparation for treating stomach-Yin deficient chronic gastritis and preparation method thereof | |
CN102688451B (en) | Chinese medicinal composition for treating alcoholic fatty liver | |
CN104606538A (en) | Traditional Chinese medicine health product for preventing and treating diabetes | |
CN105169189A (en) | Medicament for treating hypothyroidism | |
CN104707110A (en) | Traditional Chinese medicine preparation for treating pancreatic cancer and preparation method thereof | |
CN104306948A (en) | Medicament composition for treating gouty arthritis | |
CN104474478A (en) | Traditional Chinese medicine for treating non-alcoholic fatty liver disease due to qi-stagnation and blood stasis | |
CN104257986A (en) | Traditional Chinese medicine for treating nephritis | |
CN103432528A (en) | Chinese medicinal preparation for treating non-alcoholic fatty liver disease | |
CN103705856B (en) | For preventing the Chinese medicine composition of chemicotherapy acute radio-reaction | |
CN103566311A (en) | Traditional Chinese medicine composition used for curing biliary tract ascariasis | |
CN103520620B (en) | A kind of Chinese medicine preparation and preparation method for the treatment of due to weakness of spleen and stomach chronic gastritis | |
CN103393883B (en) | Chinese medicinal composition for treating neonatal jaundice | |
CN103432508B (en) | Chinese medicinal preparation used for treating stomachache | |
CN104547223A (en) | Traditional Chinese medicine for treating phlegm-blood stasis syndrome type non-alcoholic fatty liver disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150401 |